A non-inferiority trial is a type of clinical study designed to demonstrate that a new treatment is not unacceptably less effective than an existing standard treatment. The primary objective is to show that the new intervention is at least as effective as the current standard of care, within a pre-specified margin of difference.
These trials are often used when the new treatment offers other advantages, such as fewer side effects, lower cost, or easier administration. Non-inferiority trials require careful design, including the selection of an appropriate non-inferiority margin and a suitable active comparator.
Non-inferiority trials are crucial in clinical research as they allow for the evaluation of new treatments that may offer advantages beyond efficacy alone. These trials are particularly valuable when it is unethical or impractical to use a placebo control, especially in cases where effective treatments already exist.
Understanding non-inferiority trials is essential for researchers, clinicians, and regulatory bodies involved in drug development and approval processes. This knowledge enables the appropriate design, conduct, and interpretation of studies that aim to introduce new therapeutic options with potential benefits such as improved safety profiles, reduced costs, or enhanced patient compliance.
The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Copyright @ 2026 Axcellant